UnitedHealth’s Optum To Purchase Diplomat Pharmacy For About $300M

By John Heerdink LinkedIn Disclaimer

Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.

UnitedHealth’s pharmacy services unit, Optum to buy Diplomat Pharmacy (DPLO) for about $300 million after the pharmacy raised concerns to continue as a going concern after facing intense competition, as per reports. The deal was unanimously approved by Diplomat’s board of directors contemplates Optum’s move to pay $4 per share in cash for Diplomat’s outstanding common stock.

To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

nov3(13)

Post View Count : 166
(Read Original Story: UPDATE 1-UnitedHealth unit to buy Diplomat Pharmacy in $300 million deal in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us